For the twelve months ended Sep 30, 2026, ACADIA Pharmaceuticals Inc. reported $1.20B of revenue and $362.23M of net income.
ACAD revenue was $342.29M in fiscal Q3 2026 (ended Sep 30, 2026), up 22.8% from a year earlier and up 11.1% from the prior quarter. For the full fiscal 2025 it was $1.07B, up 11.9% from fiscal 2024. Compound annual growth was +19.4% over 5 years and +165.7% over 10 years. It rose in each of the last 10 fiscal years. Fiscal 2025 is the highest of the 15 fiscal years on file.
ACAD net income was $53.52M in fiscal Q3 2026 (ended Sep 30, 2026), down 25.4% from a year earlier and up 69.9% from the prior quarter. For the full fiscal 2025 it was $391.00M, up 72.7% from fiscal 2024. Fiscal 2025 is the highest of the 15 fiscal years on file.
ACAD diluted EPS was $0.31 in fiscal Q3 2026 (ended Sep 30, 2026), down 26.2% from a year earlier and up 72.2% from the prior quarter. For the full fiscal 2025 it was $2.30, up 69.1% from fiscal 2024.
ACAD free cash flow was $10.26M in fiscal Q3 2026 (ended Sep 30, 2026), down 86.1% from a year earlier and down 89.3% from the prior quarter. For the full fiscal 2025 it was $105.15M, down 33.1% from fiscal 2024.
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.07B | $957.80M | $726.44M | $517.24M | $484.14M | $441.75M | $339.08M | $223.81M | $124.90M | $17.33M |
| Cost of revenue | $89.00M | $81.84M | $41.64M | $10.17M | $19.14M | $10.21M | $11.34M | $12.38M | $9.08M | $3.08M |
| Gross profit | $982.51M | $875.96M | $684.80M | $507.07M | $473.30M | $431.54M | $327.73M | $211.43M | $115.82M | $14.25M |
| Research and development | $328.80M | $303.25M | $351.62M | $361.57M | $239.41M | $319.13M | $240.38M | $187.16M | $149.19M | $99.28M |
| Selling, general and admin | $548.89M | $488.43M | $406.56M | $369.09M | $396.03M | $388.66M | $325.64M | $265.76M | $255.06M | $186.46M |
| Operating income | $104.81M | $230.79M | -$73.38M | -$223.60M | -$170.44M | -$286.59M | -$246.54M | -$247.44M | -$292.41M | -$272.81M |
| Pre-tax income | $138.90M | $258.07M | -$51.04M | -$213.44M | -$167.52M | -$280.97M | -$234.38M | -$243.94M | -$288.28M | -$270.05M |
| Income tax | -$252.10M | $31.62M | $10.25M | $2.53M | $351.0K | $611.0K | $876.0K | $1.26M | $1.12M | $1.34M |
| Net income | $391.00M | $226.45M | -$61.29M | -$215.97M | -$167.87M | -$281.58M | -$235.26M | -$245.19M | -$289.40M | -$271.39M |
| EPS, basic | $2.32 | $1.37 | -$0.37 | -$1.34 | -$1.05 | -$1.79 | -$1.60 | -$1.94 | -$2.36 | -$2.34 |
| EPS, diluted | $2.30 | $1.36 | -$0.37 | -$1.34 | -$1.05 | -$1.79 | -$1.60 | -$1.94 | -$2.36 | -$2.34 |
| Diluted shares | 169.9M | 166.4M | 163.8M | 161.7M | 160,493 | 157,331 | 147.2M | 126.6M | 122.6M | 115.9M |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $177.69M | $319.59M | $188.66M | $114.85M | $147.44M | $326.03M | $189.68M | $134.76M | $69.42M | $163.62M |
| Receivables | $121.46M | $98.74M | $98.27M | $62.20M | $64.37M | $48.25M | $35.78M | $26.09M | $17.34M | $5.90M |
| Inventory | $111.37M | $91.69M | $40.45M | $11.56M | $14.10M | $9.68M | $6.34M | $4.07M | $5.25M | $4.17M |
| Current assets | $1.06B | $938.32M | $616.13M | $507.94M | $617.82M | $717.62M | $760.25M | $526.11M | $373.48M | $547.90M |
| Total assets | $1.56B | $1.19B | $748.96M | $587.81M | $700.12M | $782.62M | $783.18M | $540.20M | $384.51M | $561.15M |
| Current liabilities | $277.11M | $394.87M | $254.25M | $125.63M | $96.07M | $105.97M | $74.83M | $59.56M | $49.03M | $42.59M |
| Total liabilities | $336.81M | $454.96M | $317.20M | $187.40M | $159.23M | $155.61M | $84.05M | $61.12M | $49.22M | $42.74M |
| Shareholders' equity | $1.23B | $732.79M | $431.75M | $400.41M | $540.89M | $627.01M | $699.13M | $479.08M | $335.29M | $518.41M |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $109.84M | $157.72M | $16.70M | -$114.03M | -$125.66M | -$136.17M | -$151.13M | -$167.47M | -$217.76M | -$208.41M |
| Capital expenditures | $4.69M | $523.0K | $50.0K | $0 | $1.12M | $7.59M | $1.13M | $2.10M | $812.0K | $1.51M |
| Free cash flow | $105.15M | $157.20M | $16.65M | -$114.03M | -$126.78M | -$143.75M | -$152.26M | -$169.57M | -$218.57M | -$209.91M |
| Investing cash flow | -$302.56M | -$30.54M | $32.00M | $73.24M | -$71.10M | $192.51M | -$165.84M | -$71.49M | $92.47M | -$261.92M |
| Financing cash flow | $49.88M | $6.84M | $25.13M | $8.20M | $18.16M | $81.00M | $371.85M | $306.65M | $31.19M | $533.81M |
| Stock-based compensation | $52.13M | $67.05M | $66.42M | $68.20M | $63.62M | $84.42M | $82.27M | $81.56M | $75.53M | $55.27M |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | 11.9% | 31.8% | 40.4% | 6.8% | 9.6% | 30.3% | 51.5% | 79.2% | 620.7% | 28311.5% |
| Net income growth, YoY | 72.7% | - | - | - | - | - | - | - | - | - |
| EPS growth, YoY | 69.1% | - | - | - | - | - | - | - | - | - |
| Gross margin | 91.7% | 91.5% | 94.3% | 98.0% | 97.8% | 97.7% | 96.7% | 94.5% | 92.7% | 82.2% |
| Operating margin | 9.8% | 24.1% | -10.1% | -43.2% | -35.2% | -64.9% | -72.7% | -110.6% | -234.1% | -1574.1% |
| Net margin | 36.5% | 23.6% | -8.4% | -41.8% | -34.7% | -63.7% | -69.4% | -109.6% | -231.7% | -1565.9% |
| Free cash flow margin | 9.8% | 16.4% | 2.3% | -22.0% | -26.2% | -32.5% | -44.9% | -75.8% | -175.0% | -1211.2% |
| Return on equity | 31.9% | 30.9% | -14.2% | -53.9% | -31.0% | -44.9% | -33.7% | -51.2% | -86.3% | -52.4% |
| Return on assets | 25.0% | 19.1% | -8.2% | -36.7% | -24.0% | -36.0% | -30.0% | -45.4% | -75.3% | -48.4% |
| Current ratio | 3.83 | 2.38 | 2.42 | 4.04 | 6.43 | 6.77 | 10.16 | 8.83 | 7.62 | 12.87 |
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $342.29M | $307.96M | $268.06M | $283.99M | $278.63M | $264.57M | $244.32M | $259.60M | $250.40M | $241.96M | $205.83M | $231.04M |
| Cost of revenue | $35.09M | $28.32M | $24.79M | $26.23M | $21.65M | $20.73M | $20.39M | $21.80M | $18.86M | $18.23M | $22.95M | $17.89M |
| Gross profit | $307.20M | $279.64M | $243.27M | $257.76M | $256.99M | $243.83M | $223.93M | $237.80M | $231.54M | $223.73M | $182.88M | $213.15M |
| Research and development | $76.28M | $81.56M | $76.87M | $84.76M | $87.83M | $77.95M | $78.27M | $100.73M | $66.61M | $76.23M | $59.68M | $66.74M |
| Selling, general and admin | $159.20M | $160.25M | $171.02M | $155.62M | $133.40M | $133.51M | $126.37M | $130.08M | $133.29M | $117.06M | $107.99M | $111.47M |
| Operating income | $71.72M | $37.84M | -$4.62M | $17.39M | $35.76M | $32.37M | $19.29M | $153.50M | $31.64M | $30.44M | $15.21M | $34.94M |
| Pre-tax income | $80.44M | $46.47M | $3.98M | $26.32M | $44.59M | $40.21M | $27.78M | $161.09M | $38.81M | $37.18M | $21.00M | $39.70M |
| Income tax | $26.91M | $14.97M | $344.0K | -$247.25M | -$27.18M | $13.54M | $8.79M | $17.34M | $6.04M | $3.79M | $4.45M | -$6.09M |
| Net income | $53.52M | $31.50M | $3.64M | $273.57M | $71.78M | $26.67M | $18.99M | $143.74M | $32.77M | $33.39M | $16.55M | $45.80M |
| EPS, basic | $0.31 | $0.18 | $0.02 | $1.62 | $0.43 | $0.16 | $0.11 | $0.87 | $0.20 | $0.20 | $0.10 | $0.28 |
| EPS, diluted | $0.31 | $0.18 | $0.02 | $1.61 | $0.42 | $0.16 | $0.11 | $0.86 | $0.20 | $0.20 | $0.10 | $0.28 |
| Diluted shares | 175.5M | 172.9M | 172.7M | - | 170.7M | 168.7M | 167.7M | - | 166.2M | 166.2M | 166.6M | - |
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $322.37M | $384.99M | $282.21M | $177.69M | $258.00M | $253.64M | $217.70M | $319.59M | $155.15M | $177.13M | $204.75M | $188.66M |
| Receivables | $161.02M | $150.64M | $135.35M | $121.46M | $115.85M | $107.50M | $105.74M | $98.74M | $98.21M | $103.70M | $94.70M | $98.27M |
| Inventory | $106.84M | $108.67M | $112.29M | $111.37M | $105.98M | $110.53M | $102.97M | $91.69M | $86.74M | $86.07M | $66.64M | $40.45M |
| Current assets | $1.27B | $1.22B | $1.10B | $1.06B | $1.08B | $960.55M | $870.94M | $938.32M | $788.28M | $728.92M | $675.30M | $616.13M |
| Total assets | $1.79B | $1.74B | $1.61B | $1.56B | $1.33B | $1.23B | $1.13B | $1.19B | $976.87M | $914.10M | $855.10M | $748.96M |
| Current liabilities | $332.22M | $361.44M | $305.52M | $277.11M | $356.58M | $330.02M | $302.53M | $394.87M | $343.94M | $337.85M | $330.60M | $254.25M |
| Total liabilities | $406.66M | $436.29M | $357.16M | $336.81M | $413.50M | $403.17M | $367.13M | $454.96M | $399.69M | $397.40M | $391.06M | $317.20M |
| Shareholders' equity | $1.39B | $1.31B | $1.25B | $1.23B | $917.27M | $822.38M | $765.24M | $732.79M | $577.18M | $516.70M | $464.04M | $431.75M |
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $11.50M | $100.78M | $33.98M | -$48.73M | $74.29M | $63.96M | $20.32M | $40.38M | $63.25M | $25.01M | $29.08M | $85.39M |
| Capital expenditures | $1.24M | $5.09M | $5.21M | $4.00M | $388.0K | $297.0K | $0 | $453.0K | $70.0K | - | - | $0 |
| Free cash flow | $10.26M | $95.69M | $28.77M | -$52.74M | $73.90M | $63.66M | $20.32M | $39.93M | $63.18M | - | - | $85.39M |
| Investing cash flow | -$86.15M | -$8.53M | $66.28M | -$55.87M | -$79.35M | -$43.29M | -$124.05M | $122.15M | -$82.46M | -$56.19M | -$14.04M | -$347.0K |
| Financing cash flow | $11.87M | $10.49M | $4.23M | $22.67M | $9.42M | $15.96M | $1.84M | $1.97M | $268.0K | $3.56M | $1.04M | $5.43M |
| Stock-based compensation | $17.45M | $16.94M | $14.70M | $13.23M | $13.18M | $14.34M | $11.38M | $10.45M | $26.16M | $15.69M | $14.75M | $18.02M |
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | 22.8% | 16.4% | 9.7% | 9.4% | 11.3% | 9.3% | 18.7% | 12.4% | 18.3% | 46.4% | 73.8% | 69.3% |
| Net income growth, YoY | -25.4% | 18.1% | -80.8% | 90.3% | 119.1% | -20.1% | 14.7% | 213.9% | - | 2897.2% | - | - |
| EPS growth, YoY | -26.2% | 12.5% | -81.8% | 87.2% | 110.0% | -20.0% | 10.0% | 207.1% | - | 1900.0% | - | - |
| Gross margin | 89.7% | 90.8% | 90.8% | 90.8% | 92.2% | 92.2% | 91.7% | 91.6% | 92.5% | 92.5% | 88.8% | 92.3% |
| Operating margin | 21.0% | 12.3% | -1.7% | 6.1% | 12.8% | 12.2% | 7.9% | 59.1% | 12.6% | 12.6% | 7.4% | 15.1% |
| Net margin | 15.6% | 10.2% | 1.4% | 96.3% | 25.8% | 10.1% | 7.8% | 55.4% | 13.1% | 13.8% | 8.0% | 19.8% |
| Free cash flow margin | 3.0% | 31.1% | 10.7% | -18.6% | 26.5% | 24.1% | 8.3% | 15.4% | 25.2% | - | - | 37.0% |
| Current ratio | 3.82 | 3.39 | 3.59 | 3.83 | 3.02 | 2.91 | 2.88 | 2.38 | 2.29 | 2.16 | 2.04 | 2.42 |
Source: XBRL data ACADIA Pharmaceuticals Inc. files with the SEC, latest filing dated Nov 5, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| ACAD | $1.20B | +14.8% | $362.23M | 30.1% | $2.85B |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.33T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $679.13B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $518.44B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $366.73B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $312.35B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $293.69B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.40B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $183.23B |